Siteadmin, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators
125,794
edits
Changes
Jump to navigation
Jump to search
Line 2:
Line 2: − + Line 20:
Line 20: + + + − +
quercetin
Numerous '''coronavirus studies''' demonstrate the prophylactic and early use effectiveness of [[hydroxychloroquine]] (HCQ) against [[COVID-19]], which are being ignored or downplayed for political reasons.
Numerous '''coronavirus studies''' demonstrate the prophylactic and early use effectiveness of [[hydroxychloroquine]] (HCQ) against [[COVID-19]], which are being ignored or downplayed for political reasons.
Here is a sampling of the growing list of valid studies confirming the effectiveness of zinc and hydroxychloroquine against COVID-19:
Here is a sampling of the growing list of valid studies confirming the effectiveness of zinc, hydroxychloroquine, and other vitamins or medication against COVID-19:
== Compilation ==
== Compilation ==
{{cquote|In univariate analyses, zinc sulfate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU, and mortality or transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at which zinc sulfate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) reduction in mortality or transfer to hospice remained significant (OR 0.449, 95% CI 0.271-0.744). Conclusion: This study provides the first in vivo evidence that zinc sulfate in combination with hydroxychloroquine may play a role in therapeutic management for COVID-19.<ref>https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001250</ref><ref>https://www.medrxiv.org/content/10.1101/2020.05.02.20080036v1</ref>}}
{{cquote|In univariate analyses, zinc sulfate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU, and mortality or transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at which zinc sulfate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) reduction in mortality or transfer to hospice remained significant (OR 0.449, 95% CI 0.271-0.744). Conclusion: This study provides the first in vivo evidence that zinc sulfate in combination with hydroxychloroquine may play a role in therapeutic management for COVID-19.<ref>https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001250</ref><ref>https://www.medrxiv.org/content/10.1101/2020.05.02.20080036v1</ref>}}
== Quercetin ==
{{cquote|Quercetin has a theoretical, but significant, capability to interfere with SARS‐CoV‐2 replication, with the results showing this to be the fifth best compound out of 18 candidates. ... A randomised study performed a decade ago [on a virus other than coronavirus] enrolled 1,002 adult subjects affected by viral infections of the upper respiratory tract; this showed that quercetin administered at very high dosages (1,000 mg/dose) for 12 weeks reduced the days of illness in middle‐aged and elderly subjects (Heinz et al., 2010).<ref>https://onlinelibrary.wiley.com/doi/10.1002/ptr.6887</ref>}}
== Saudi Arabia ==
== Saudi Arabia ==
An observational prospective cohort study examined in 238 ambulatory fever clinics in Saudi Arabia, based on the Ministry of Health (MOH) [[COVID-19]] treatment guidelines.
An observational prospective cohort study examined 238 ambulatory fever clinics in Saudi Arabia, based on the Ministry of Health (MOH) [[COVID-19]] treatment guidelines.
The comparison was between 1,817 patients in the [[HCQ]] group vs 3,724 in the merely supportive care ("SC") group.
The comparison was between 1,817 patients in the [[HCQ]] group vs 3,724 in the merely supportive care ("SC") group.